Corey Roos1,2, Elena Stein1,2, Sarah Bowen3, Katie Witkiewitz1,2. 1. Department of Psychology, University of New Mexico, MSC 03-2220, Albuquerque NM, 87131. 2. Center on Alcoholism, Substance Abuse, and Addictions, University of New Mexico, 2650 Yale Blvd SE, Albuquerque NM, 87106. 3. School of Graduate Psychology, Pacific University, 190 SE 8th Avenue, Hillsboro OR 97123.
Abstract
OBJECTIVES: Mindfulness-based relapse prevention (MBRP) is an effective group-based aftercare treatment for substance use disorders (SUDs), yet few studies have examined moderators of MBRP efficacy. This secondary data analysis evaluated individual gender and group gender composition (e.g., proportion of women relative to men in each therapy group) as treatment moderators of MBRP. METHODS: The analysis sample included 186 individuals with SUDs randomized to MBRP or relapse prevention (RP) as an aftercare treatment. Outcomes included number of heavy drinking days and drug use days at the 12-month follow-up. RESULTS: There were no treatment moderation effects for models with heavy drinking days as the outcome (all ps > .05). Group gender composition, but not individual gender, moderated the effect of treatment condition on drug use days (p < .01). Individuals who received MBRP had significantly fewer drug use days at 12-months than those who received RP, but only among individuals in therapy groups comprising one-third or more women (p <0 .0001). Specifically, all women and men who received MBRP in groups with one-third or more women were abstinent from drugs at month 12, whereas those in RP groups with one-third or more women had an average of about eight drug use days at month 12 (corresponding to a large between-treatment condition effect size). CONCLUSIONS: Group-based MBRP may be more efficacious than group-based RP, particularly when women compose at least one-third of the therapy group. Further research is warranted on gender and group gender composition as moderators of MBRP.
OBJECTIVES: Mindfulness-based relapse prevention (MBRP) is an effective group-based aftercare treatment for substance use disorders (SUDs), yet few studies have examined moderators of MBRP efficacy. This secondary data analysis evaluated individual gender and group gender composition (e.g., proportion of women relative to men in each therapy group) as treatment moderators of MBRP. METHODS: The analysis sample included 186 individuals with SUDs randomized to MBRP or relapse prevention (RP) as an aftercare treatment. Outcomes included number of heavy drinking days and drug use days at the 12-month follow-up. RESULTS: There were no treatment moderation effects for models with heavy drinking days as the outcome (all ps > .05). Group gender composition, but not individual gender, moderated the effect of treatment condition on drug use days (p < .01). Individuals who received MBRP had significantly fewer drug use days at 12-months than those who received RP, but only among individuals in therapy groups comprising one-third or more women (p <0 .0001). Specifically, all women and men who received MBRP in groups with one-third or more women were abstinent from drugs at month 12, whereas those in RP groups with one-third or more women had an average of about eight drug use days at month 12 (corresponding to a large between-treatment condition effect size). CONCLUSIONS: Group-based MBRP may be more efficacious than group-based RP, particularly when women compose at least one-third of the therapy group. Further research is warranted on gender and group gender composition as moderators of MBRP.
Entities:
Keywords:
gender; group psychotherapy; mindfulness-based relapse prevention; substance use disorder; treatment moderators
Authors: Anita Williams Woolley; Christopher F Chabris; Alex Pentland; Nada Hashmi; Thomas W Malone Journal: Science Date: 2010-09-30 Impact factor: 47.728
Authors: Shelly F Greenfield; Amanda M Cummings; Laura E Kuper; Sara B Wigderson; Mirka Koro-Ljungberg Journal: Subst Use Misuse Date: 2013-04-22 Impact factor: 2.164
Authors: Shelly F Greenfield; Dawn E Sugarman; Cathryn M Freid; Genie L Bailey; Michele A Crisafulli; Julia S Kaufman; Sara Wigderson; Hilary S Connery; John Rodolico; Antonio A Morgan-Lopez; Garrett M Fitzmaurice Journal: Drug Alcohol Depend Date: 2014-07-04 Impact factor: 4.492
Authors: Sarah Bowen; Neharika Chawla; Susan E Collins; Katie Witkiewitz; Sharon Hsu; Joel Grow; Seema Clifasefi; Michelle Garner; Anne Douglass; Mary E Larimer; Alan Marlatt Journal: Subst Abus Date: 2009 Oct-Dec Impact factor: 3.716
Authors: Shelly F Greenfield; Jennifer Sharpe Potter; Melissa F Lincoln; Rebecca E Popuch; Laura Kuper; Robert J Gallop Journal: Am J Drug Alcohol Abuse Date: 2008 Impact factor: 3.829
Authors: Tracey A Garcia; Guadalupe A Bacio; Kristin Tomlinson; Benjamin O Ladd; Kristen G Anderson Journal: Exp Clin Psychopharmacol Date: 2015-08 Impact factor: 3.157
Authors: Shelly F Greenfield; Elisa M Trucco; R Kathryn McHugh; Melissa Lincoln; Robert J Gallop Journal: Drug Alcohol Depend Date: 2007-04-18 Impact factor: 4.492
Authors: Sarah Bowen; Katie Witkiewitz; Seema L Clifasefi; Joel Grow; Neharika Chawla; Sharon H Hsu; Haley A Carroll; Erin Harrop; Susan E Collins; M Kathleen Lustyk; Mary E Larimer Journal: JAMA Psychiatry Date: 2014-05 Impact factor: 21.596
Authors: Simon B Goldberg; Brian Pace; Matas Griskaitis; Reinhard Willutzki; Nicole Skoetz; Sven Thoenes; Aleksandra E Zgierska; Susanne Rösner Journal: Cochrane Database Syst Rev Date: 2021-10-20
Authors: Hugo S Gomes; David P Farrington; Marvin D Krohn; Ana Cunha; Julia Jurdi; Bárbara Sousa; Diogo Morgado; Joseph Hoft; Elizabeth Hartsell; Leigh Kassem; Ângela Maia Journal: J Exp Criminol Date: 2022-09-21